Protagonist Therapeutics Inc (PTGX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Protagonist Therapeutics Inc (PTGX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9836
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Protagonist Therapeutics Inc (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist’s peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. The company’s product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and disorders. It operates in the US and Australia. Protagonist is headquartered in Milpitas, California, the US.

Protagonist Therapeutics Inc (PTGX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Protagonist Therapeutics Raises USD40 Million in Series C Financing 11
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 13
Partnerships 14
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
Licensing Agreements 15
Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 15
Equity Offering 17
Protagonist Therapeutics to Raise USD22 Million in Private Placement of Shares 17
Protagonist Therapeutics Prices Public Offering of Shares for USD60 Million 18
Protagonist Therapeutics Raises USD90 Million in IPO 19
Protagonist Therapeutics Inc – Key Competitors 21
Protagonist Therapeutics Inc – Key Employees 22
Protagonist Therapeutics Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 07, 2018: Protagonist Therapeutics reports second quarter 2018 financial results 24
May 09, 2018: Protagonist Therapeutics Reports First Quarter 2018 Financial Results 26
Mar 07, 2018: Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results 28
Nov 06, 2017: Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 30
Aug 08, 2017: Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights 32
May 10, 2017: Protagonist Therapeutics Reports First Quarter 2017 Financial Results 34
Mar 07, 2017: Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results 35
Corporate Communications 36
May 24, 2018: Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer 36
May 16, 2018: Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors 37
Dec 14, 2017: Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors 38
Jun 08, 2017: Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. “Rusty” Williams, to its Board of Directors 39
Product News 40
09/06/2018: Protagonist Therapeutics receives $1.45 million SBIR funding for the development of PTG-300 40
Product Approvals 41
Mar 06, 2018: FDA Grants Orphan Drug Designation for Protagonist Therapeutics’ PTG-300 for the Treatment of Beta-Thalassemia 41
Clinical Trials 42
Sep 27, 2018: Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300 42
Jun 18, 2018: Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting 43
May 17, 2018: Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association 44
Dec 14, 2017: Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 45
Sep 20, 2017: Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 46
May 25, 2017: Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protagonist Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Protagonist Therapeutics Raises USD40 Million in Series C Financing 11
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 13
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 15
Protagonist Therapeutics to Raise USD22 Million in Private Placement of Shares 17
Protagonist Therapeutics Prices Public Offering of Shares for USD60 Million 18
Protagonist Therapeutics Raises USD90 Million in IPO 19
Protagonist Therapeutics Inc, Key Competitors 21
Protagonist Therapeutics Inc, Key Employees 22
Protagonist Therapeutics Inc, Subsidiaries 23

List of Figures
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Protagonist Therapeutics Inc (PTGX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MVV Energie AG (MVV1):企業の財務・戦略的SWOT分析
    MVV Energie AG (MVV1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Country Road Group Pty Ltd:企業の戦略的SWOT分析
    Country Road Group Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Check Point Software Technologies Ltd (CHKP):企業の財務・戦略的SWOT分析
    Check Point Software Technologies Ltd (CHKP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Daido Steel Co., Ltd.:企業の戦略・SWOT・財務分析
    Daido Steel Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daido Steel Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sembcorp Industries Ltd (U96)-石油・ガス分野:企業M&A・提携分析
    Summary Sembcorp Industries Limited (Sembcorp) is a diversified energy, water and marine company. The company’s utilities division provides energy and water to industrial and municipal customers. Its energy operations include power generation, steam production and supply and natural gas import suppl …
  • Antero Resources Corp (AR):石油・ガス:M&Aディール及び事業提携情報
    Summary Antero Resources Corp (Antero) is an independent oil and natural gas company that explores, develops, produces and sells natural gas and oil from the Appalachia Basin. It gather and process wellhead natural gas and produce natural gas liquids (NGLs). The company also purchases and sells thir …
  • Raschig GmbH:企業の戦略的SWOT分析
    Raschig GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Tele2 AB (TEL2 B):企業の財務・戦略的SWOT分析
    Tele2 AB (TEL2 B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Wynn Macau Ltd:企業の戦略・SWOT・財務情報
    Wynn Macau Ltd - Strategy, SWOT and Corporate Finance Report Summary Wynn Macau Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • 3D Oil Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    3D Oil Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary 3D Oil Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational a …
  • Hoteli-Metropol AD Ohrid:企業の戦略・SWOT・財務情報
    Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report Summary Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Wynn Macau Ltd:企業の戦略・SWOT・財務分析
    Wynn Macau Ltd - Strategy, SWOT and Corporate Finance Report Summary Wynn Macau Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Associated Milk Producers Inc.:企業の戦略・SWOT・財務情報
    Associated Milk Producers Inc. - Strategy, SWOT and Corporate Finance Report Summary Associated Milk Producers Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • American Outdoor Brands Corp:企業の戦略・SWOT・財務情報
    American Outdoor Brands Corp - Strategy, SWOT and Corporate Finance Report Summary American Outdoor Brands Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • ACell Inc:企業の製品パイプライン分析
    Summary ACell Inc (ACell) is a medical device company that offers products for wounds and various surgical procedures. The company develops and manufactures products to facilitate the body’s ability to repair and remodel tissue. Its products portfolio includes burn matrix products, multilayer wound …
  • TriWest Healthcare Alliance Corp:企業の戦略的SWOT分析
    TriWest Healthcare Alliance Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Park City Group Inc (PCYG):企業の財務・戦略的SWOT分析
    Summary Park City Group Inc (Park City) is a technology company that provides supply chain, merchandising and store level solutions. The company offers scan based trading, vendor managed inventory, DSD visibility and strategic analysis, distribution center procurement, store level replenishment, ent …
  • Micro Labs Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Micro Labs Ltd (Micro Labs) is a healthcare service organization which conducts research and development of bio equivalent generics. The organization’s business segments include formulations and active pharmaceutical ingredients. Its products include acetamide, allercet, amiodar, amlong, aml …
  • MSC Crociere S.A.:企業の戦略・SWOT・財務情報
    MSC Crociere S.A. - Strategy, SWOT and Corporate Finance Report Summary MSC Crociere S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Transmissora Alianca de Energia Eletrica SA (TAEE11):企業の財務・戦略的SWOT分析
    Transmissora Alianca de Energia Eletrica SA (TAEE11) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆